MacManus Michael, Everitt Sarah
Department of Radiation Oncology, Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australia; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria 3010, Australia.
Department of Radiation Oncology, Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australia; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria 3010, Australia.
PET Clin. 2018 Jan;13(1):43-57. doi: 10.1016/j.cpet.2017.08.005. Epub 2017 Oct 20.
PET scanning plays key roles in planning the management of patients with lung cancer who are candidates for curative-intent treatment with radiotherapy and has contributed to improvements in survival. F-fluorodeoxyglucose-PET is the most important modality for staging, patient selection, and radiotherapy target volume definition in patients with unresectable non-small cell lung cancer. Developments include the availability of alternative tracers, such as F-fluorothymidine, for imaging proliferation and a range of hypoxia imaging agents. The role of response-adapted therapy, based on interim PET scans performed during the treatment course, is being explored as a way of improving local disease control.
正电子发射断层扫描（PET）在为有放疗治愈意向的肺癌患者制定治疗方案中发挥着关键作用，并有助于提高生存率。氟脱氧葡萄糖-PET是不可切除非小细胞肺癌患者分期、患者选择及放疗靶区定义的最重要方式。发展包括有替代示踪剂，如用于增殖成像的氟代胸苷，以及一系列缺氧显像剂。基于治疗过程中进行的中期PET扫描的适应性反应治疗的作用，正作为一种改善局部疾病控制的方法进行探索。
